| Předmět: |
|
| Zdroj: |
Drug Week; 6/28/2024, p1225-1225, 1p |
| Abstrakt: |
A recent report from the National University of Pharmacy discusses the potential benefits of dipeptidyl peptidase 4 (DPP4) inhibitors in addition to their role in improving glycemic control. The researchers constructed potential candidates for DPP4 inhibitors based on structural prerequisites and evolutionary paths. In silico assessment of the compounds showed favorable characteristics, and molecular docking predicted the likely inhibition of DPP4. The study identified a promising DPP4 inhibitor among the tested compounds. For more information, readers can refer to the journal article published by the National University of Pharmacy. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
